Next Science (ASX:NXS) ROE % Adjusted to Book Value : -30.80% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Next Science ROE % Adjusted to Book Value?

Next Science's ROE % for the quarter that ended in Dec. 2024 was -186.31%. Next Science's PB Ratio for the quarter that ended in Dec. 2024 was 6.05. Next Science's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -30.80%.

Next Science ROE % Adjusted to Book Value Historical Data

The historical data trend for Next Science's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science ROE % Adjusted to Book Value Chart

Next Science Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-6.13

-3.97

-11.20

-30.39

-22.47

Next Science Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial							-9.00	-	-46.45	-18.09	-30.80

Competitive Comparison of Next Science's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Next Science's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Next Science's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Next Science ROE % Adjusted to Book Value Calculation

Next Science's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-135.95%	/	6.05
	=	-22.47%

Next Science's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-186.31%	/	6.05
	=	-30.80%

Next Science ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Next Science's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Next Science Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

NXSCF:USA

Address

264-278 George Street, Level 14, Australia Square, HWL Ebsworth, Sydney, NSW, AUS, 2000

Website

https://www.nextscience.com

Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.

Next Science Headlines

No Headlines